> Eli Lilly has filed a patent dispute against Adocia. The action adds another front to the legal tussle between the former partners. Statement
> The EMA delayed its decision about the conditional approval of Kiadis’ blood cancer drug ATIR101 until the first half of next year. Despite the setback, Kiadis still expects to introduce the product in the second half of 2019. Release
> Acacia Pharma revealed that it expects a speedy resolution to the manufacturing issues that led the FDA to reject a filing for approval of Barhemsys. The company aims to introduce the drug in the first half of next year. Statement
> Themis Bioscience outlined plans to file an IPO in Amsterdam. The listing will give the Austrian biotech the means to run a phase 3 trial of its chikungunya vaccine candidate. Release
> UCB committed to move rozanolixizumab forward in myasthenia gravis despite missing the primary endpoint in a phase 2 trial. Statement
> Diurnal talked up its prospects of filing for approval of Chronocort in Europe next year despite the drug falling short in a recent phase 3 trial. Release